PL1948131T3 - Farmaceutyczna kompozycja, wolna od dekspantenolu, jonów wapnia i fosforanów, oraz zastosowanie wapniowego środka chelatotwórczego i oftalmologicznie zgodnego regulatora lepkości - Google Patents

Farmaceutyczna kompozycja, wolna od dekspantenolu, jonów wapnia i fosforanów, oraz zastosowanie wapniowego środka chelatotwórczego i oftalmologicznie zgodnego regulatora lepkości

Info

Publication number
PL1948131T3
PL1948131T3 PL06818627T PL06818627T PL1948131T3 PL 1948131 T3 PL1948131 T3 PL 1948131T3 PL 06818627 T PL06818627 T PL 06818627T PL 06818627 T PL06818627 T PL 06818627T PL 1948131 T3 PL1948131 T3 PL 1948131T3
Authority
PL
Poland
Prior art keywords
phosphate
calcium
pharmaceutical composition
chelating agent
dexpanthenol
Prior art date
Application number
PL06818627T
Other languages
English (en)
Other versions
PL1948131T6 (pl
Inventor
Frank Holzer
Dorothea Gross
Original Assignee
Ursapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37989463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1948131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ursapharm Arzneimittel Gmbh filed Critical Ursapharm Arzneimittel Gmbh
Publication of PL1948131T3 publication Critical patent/PL1948131T3/pl
Publication of PL1948131T6 publication Critical patent/PL1948131T6/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL06818627T 2005-11-17 2006-11-17 Farmaceutyczna kompozycja, wolna od dekspantenolu, jonów wapnia i fosforanów, oraz zastosowanie wapniowego środka chelatotwórczego i oftalmologicznie zgodnego regulatora lepkości PL1948131T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005055275A DE102005055275A1 (de) 2005-11-17 2005-11-17 Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
PCT/EP2006/011053 WO2007057201A2 (de) 2005-11-17 2006-11-17 Dexpanthenol-, calciumionen- und phosphatfreie pharmazeutische zusammensetzung sowie verwendung von calcium-chelatbildner und ophthalmologisch verträglichem viskositätsregler
EP06818627A EP1948131B3 (de) 2005-11-17 2006-11-17 Dexpanthenol-, calciumionen- und phosphatfreie pharmazeutische zusammensetzung sowie verwendung von calcium-chelatbildner und ophthalmologisch verträglichem viskositätsregler

Publications (2)

Publication Number Publication Date
PL1948131T3 true PL1948131T3 (pl) 2009-08-31
PL1948131T6 PL1948131T6 (pl) 2013-09-30

Family

ID=37989463

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06818627T PL1948131T6 (pl) 2005-11-17 2006-11-17 Farmaceutyczna kompozycja, wolna od dekspantenolu, jonów wapnia i fosforanów, oraz zastosowanie wapniowego środka chelatotwórczego i oftalmologicznie zgodnego regulatora lepkości

Country Status (15)

Country Link
US (1) US8648057B2 (pl)
EP (1) EP1948131B3 (pl)
JP (1) JP2009515921A (pl)
CN (1) CN101312711B (pl)
AT (1) ATE425742T1 (pl)
CA (1) CA2630193C (pl)
CY (1) CY1109112T1 (pl)
DE (2) DE102005055275A1 (pl)
DK (1) DK1948131T3 (pl)
ES (1) ES2324118T7 (pl)
HK (1) HK1125027A1 (pl)
PL (1) PL1948131T6 (pl)
PT (1) PT1948131E (pl)
SI (1) SI1948131T1 (pl)
WO (1) WO2007057201A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20070208A1 (it) * 2007-06-19 2008-12-20 Alessandro Filippo Metodo di umidificazione di una lente a contatto
BRPI0914192A2 (pt) 2008-09-22 2015-11-03 Biochemics Inc distribuição transdérmica de fármaco usando um osmólito e agente vasoativo
DE102009021372A1 (de) 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
AT511164A1 (de) 2011-03-03 2012-09-15 Croma Pharma Gmbh Verwendung eines viskoelastischen fluids zur herstellung eines medizinproduktes für die chirurgische behandlung des auges
WO2015006460A1 (en) 2013-07-10 2015-01-15 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
FR3019465B1 (fr) 2014-04-02 2017-06-23 Horus Pharma Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen
EP3842047A1 (en) 2015-09-24 2021-06-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
ITUB20160543A1 (it) * 2016-02-08 2017-08-08 Sooft Italia S P A 63833 Montegiorgio Fermo / Italia Composizione oftalmica stabilizzante e reintegrante del film lacrimale per uso nella prevenzione delle infezioni virali
JP7258778B2 (ja) 2017-03-05 2023-04-17 レスデブコ リサーチ アンド ディベロップメント カンパニー リミテッド 感染によるものではない刺激の治療のための点眼剤
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EA202092472A1 (ru) * 2018-04-18 2021-03-25 Ай.КОМ МЕДИКАЛ ГМБХ Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
US20210228516A1 (en) * 2018-05-01 2021-07-29 Jinan Cao Eye drops that cure cataracts presbyopia and
RU2679319C1 (ru) * 2018-11-27 2019-02-07 Илья Александрович Марков Гелеобразная искусственная слеза с антисептическим и репаративным действием

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
EP0145710A1 (en) * 1983-05-25 1985-06-26 Alcon Laboratories, Inc. Ophthalmic solution
US4629623A (en) 1984-06-11 1986-12-16 Biomatrix, Inc. Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
US6271216B1 (en) * 1989-07-24 2001-08-07 Allergan Stable solution of hyaluronate in a balanced salt medium
DE69017559T3 (de) * 1989-07-24 2002-06-06 Allergan Pharmaceuticals Irela Stabile Lösung von Hyaluronat in einem isotonen Salzmilieu.
EP0464727B1 (en) * 1990-06-29 1996-01-03 Santen Pharmaceutical Co., Ltd. Use of a composition for the preparation of a medicament for debridment of retained lens material
JPH0748262A (ja) 1993-06-04 1995-02-21 Senju Pharmaceut Co Ltd 外眼部投与用組成物
IT1273011B (it) 1994-07-25 1997-07-01 Trhecnopharma S A Preparato oftalmico per l'uso come lacrima artificiale
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
WO2002015828A2 (en) * 2000-08-21 2002-02-28 Bausch & Lomb Surgical, Inc. Prevention of posterior capsular opacification by endocapsular circulation of chemical agents
AU2002228449B2 (en) * 2001-01-09 2007-12-06 Louis Johan Wagenaar Procedure and composition of treatment and/or care of the eye
JP2003002837A (ja) * 2001-06-21 2003-01-08 Lion Corp 水性外用剤組成物及び液体組成物の白濁防止方法
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
JP2003206241A (ja) * 2002-01-11 2003-07-22 Teika Seiyaku Kk 眼科用剤
JP4263456B2 (ja) * 2002-03-18 2009-05-13 わかもと製薬株式会社 ヒアルロン酸含有熱ゲル化製剤
JP2004059432A (ja) * 2002-06-04 2004-02-26 Rohto Pharmaceut Co Ltd 角膜障害治療剤
WO2004039403A1 (ja) * 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. 角膜障害治療剤
GB0225518D0 (en) 2002-11-01 2002-12-11 Airbus Uk Ltd Welding method
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP1681065A4 (en) * 2003-10-31 2011-12-28 Wakamoto Pharma Co Ltd WATER-BASED COMPOSITION SUBJECTED TO REVERSIBLE THERMOREGULATION
JP2005239622A (ja) * 2004-02-26 2005-09-08 Rohto Pharmaceut Co Ltd 角膜障害治療剤
US20110212899A1 (en) * 2004-04-23 2011-09-01 Yoshiko Takayama Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes

Also Published As

Publication number Publication date
DE502006003215D1 (de) 2009-04-30
EP1948131A2 (de) 2008-07-30
SI1948131T1 (sl) 2009-08-31
DK1948131T3 (da) 2009-07-13
ES2324118T3 (es) 2009-07-30
WO2007057201A3 (de) 2007-08-02
EP1948131B1 (de) 2009-03-18
WO2007057201A2 (de) 2007-05-24
PL1948131T6 (pl) 2013-09-30
DE102005055275A1 (de) 2007-05-24
EP1948131B3 (de) 2013-03-27
CN101312711B (zh) 2013-07-17
US20090111770A1 (en) 2009-04-30
JP2009515921A (ja) 2009-04-16
HK1125027A1 (en) 2009-07-31
ATE425742T1 (de) 2009-04-15
ES2324118T7 (es) 2013-07-30
US8648057B2 (en) 2014-02-11
PT1948131E (pt) 2009-06-12
CA2630193A1 (en) 2007-05-24
CY1109112T1 (el) 2014-07-02
CA2630193C (en) 2015-05-19
CN101312711A (zh) 2008-11-26

Similar Documents

Publication Publication Date Title
HK1125027A1 (en) Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
HK1129277A1 (en) Tannate salt of rasagiline
TN2009000214A1 (en) Manufacture process
TW200716201A (en) Ophthalmic devices for sustained delivery of active compounds
TW200612892A (en) Novel compounds
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
TNSN07005A1 (fr) Analogues tetrapeptidiques
MX2010004319A (es) Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
TW200732296A (en) Novel compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA200970377A1 (ru) Композиции фенилалкиламинокарбамата
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MXPA05009712A (es) Composiciones que comprenden acido hialuronico para la prevencion de infecciones urogenitales.
TW200719905A (en) Composition for treating dry eye and related methods of manufacture and methods of use
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
WO2008065485A3 (en) Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
UA96269C2 (uk) Інгібітори цистеїнпротеази та їх терапевтичне застосування
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
MY147271A (en) Accelerating agent of calcium absorption